Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC-25-2648
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
25-2648 (also known as NNC-25-2648) is a small molecule glucagon receptor antagonist (GRA) developed by Agouron Pharmaceuticals and Novo Nordisk. It selectively binds to and blocks the glucagon receptor (GCGR), inhibiting glucagon-mediated hepatic glucose production and regulating amino acid metabolism. Although initially developed as a therapeutic candidate for the treatment of type 2 diabetes, its clinical development was terminated. It remains widely utilized in preclinical research as a pharmacological tool to investigate the liver-alpha-cell axis, glucagon signaling, and metabolic pathways related to amino acid and lipid metabolism.
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on NNC-25-2648.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC-25-2648.